Interchangeability Won’t Solve US Biosimilar Market’s Woes, FDA’s Gottlieb Says
Executive Summary
FDA's Biosimilar Action Plan aims to boost approvals, but Commissioner Gottlieb says he's had a change of heart about how much impact an interchangeability designation can have on market uptake.
You may also be interested in...
Biosimilars For US Market May Be Able To Rely On EU-Licensed Reference Products
Commissioner Scott Gottlieb says move could allow biosimilar sponsors to avoid anti-competitive efforts by brand sponsors in US.
US FDA Biosimilar Guidance Update Will Relax Interchangeability Standards
Updated interchangeability guidance is one of several 'incremental reforms' agency is working on that could ease development burden for biosimilars, Commissioner Scott Gottlieb says.
Biosimilars Need Better Reimbursement, Not 'Kabuki' Coverage, Gottlieb Tells Insurers
Rebate arrangements that block biosimilar uptake under guise of lowering costs do patients no favors, US FDA Commissioner says at AHIP policy conference.